Skip to content
10-K

Annual Report

AMICUS THERAPEUTICS, INC.

0001178879-25-000003

← back to feed
Filed
Feb 19, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 10, 2025 300.12M sh
Long Term Debt FY 2024 · Dec 31, 2023 $387.86M
Current Liabilities FY 2024 · Dec 31, 2023 $167.69M
Total Liabilities FY 2024 · Dec 31, 2023 $617.71M
Current Assets FY 2024 · Dec 31, 2023 $483.06M
Total Assets FY 2024 · Dec 31, 2023 $777.88M
Shares Diluted FY 2024 · Dec 31, 2022 289.06M sh
Capex FY 2024 · Dec 31, 2022 $3.77M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$166.58M
Cash And Equivalents FY 2024 · Dec 31, 2022 $148.81M
Stockholders Equity FY 2024 · Dec 31, 2022 $123.05M
Stockholders Equity FY 2024 · Dec 31, 2021 $307.37M
Eps Diluted FY 2024 · Dec 31, 2022 −$0.82
Eps Basic FY 2024 · Dec 31, 2022 −$0.82
Sga Expense FY 2024 · Dec 31, 2022 $213.04M
Net Income FY 2024 · Dec 31, 2022 −$236.57M
Operating Income FY 2024 · Dec 31, 2022 −$212.12M
Gross Profit FY 2024 · Dec 31, 2022 $290.63M
Revenue FY 2024 · Dec 31, 2022 $329.23M